January - June · Net sales rose by about 31 percent to SEK 8,403k (6,412k). · Expenses increased by SEK 6,610 to SEK -25,101k (-18,522k). The increase relates to the settled patent dispute in the US. Excluding legal fees, Genovis reduced its expenses during the six-month period by SEK 2,058k to SEK 13,462k (15,520k). · Operating result was a loss of SEK 11,402k (loss: 10,260k). Excluding legal fees and reimbursement from the insurance company the operating result was a loss of SEK 4,861k (loss: 8,741k). · Comprehensive income was a loss of SEK 11,574k (loss: 10,355k). Excluding legal fees and reimbursement from the insurance company, comprehensive income was a loss of SEK 5,033k (loss: 8,836k). · Comprehensive income per share basic and diluted totaled SEK -0.31 (-0.45). Excluding legal fees and reimbursement from the insurance company, comprehensive income per share was a loss of SEK 0.13 (loss: 0.38). · Cash flow from operating activities during the six-month period was SEK -10,997k (-9,478). · Cash and cash equivalents including short-term investments amounted to SEK 10,011k (9,240k) at the end of the half-year. April–June · In June Genovis reached a settlement in the patent dispute with Promega Corporation and entered into a royalty-based global licensing agreement regarding the patent involved in the dispute. · In May, Genovis carried out a rights issue that was oversubscribed by 10 percent. The rights issue raised about SEK 23 million before issue expenses for the company. · Genovis launched a further development of FabULOUS®. The new product is being marketed under the name FabULOUS® kit. · Genovis launched GingisREX®, a new enzyme aimed at customers throughout the proteomics market. The products that Genovis has launched to date have solely been used for modification of antibodies, while GingisREX can be used for proteins in general. · Net sales rose by about 30 percent to SEK 4,595k (3,526k). · Comprehensive income was a loss of SEK 8,121k (loss: 5,348k). · Comprehensive income per share basic and diluted totaled SEK -0.21 (-0.22). · Cash flow from operating activities was SEK -8,499k (-4,624k). Comments from CEO Fredrik Olsson The second quarter showed continued strong sales growth for the Company’s products and was the single best quarter in the history of the Company. Sales amounted to SEK 4.6 million, an increase of 30 percent year over year and 21 percent quarter over quarter. For the six-month period as a whole sales rose 31 percent, demonstrating stable organic growth in the product portfolio. It is particularly gratifying that we see growth in all product groups during the period. At the end of the second quarter, we reached a settlement in the legal dispute that has been ongoing since 2014. We are pleased to have reached an agreement that gives us royalty income at good levels, but above all, the agreement is strategically important to increase the size of the market and to improve conditions for faster adoption of FabRICATOR in the production of antibody drugs. Now that there are two suppliers of the enzyme, the prospects have improved for the enzyme to be included in critical methods of analysis for the production of antibody-based drugs. The market for antibody-based drugs is undergoing strong growth and there is a clear need to simplify and improve the analytical methods associated with production. We are now also seeing more requests for larger volumes for use specifically in quality control in the production of antibodies, for which reason I expect continued growth for FabRICATOR since we are still in an early stage. While revenues from sales have increased sharply, the cost base--excluding the legal costs of the dispute with Promega--has declined 13 percent compared with the first half of 2015. However, the legal expenses associated with the dispute have had a negative impact on earnings for the period. As a result of the settlement, these expenses will end during the beginning of the third quarter. It is worth noting that organic growth continues without any negative effect on gross margin, indicating efficient use of resources in the production of our products and that the price level remains at a satisfactory level. As I look ahead to the rest of the year I expect continued good organic growth. We will increase our efforts in sales and marketing to further drive growth. A clearer presence in the Asian markets will be prioritized, while strengthening our own sales organization in North America and Europe. We will also continue to work to broaden the market for our existing product portfolio with new products aimed at new applications, at the same time that we follow the strategy of expanding the product portfolio by introducing new products. In line with this strategy, in the second quarter we launched two new products – GingisREX and FabULOUS Fab Kit. GingisREX opens a new market for us because the product can not only be used for antibodies, but also within general protein analysis. FabULOUS Fab Kit simplifies handling of antibody fragments for a certain type of antibody during production. In May we carried out a rights issue that was oversubscribed. The additional capital, together with the strong growth we continue to demonstrate, will provide good conditions for further investments in market expansion and a continued positive trend for Genovis. I would like to thank all of our engaged shareholders and dedicated employees for their efforts, which have resulted in yet another successful six months and created good prospects for a positive development moving forward. For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com) This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on August 28, 2016. ABOUT GENOVIS Genovis is a global company that offers enzyme products that facilitate development and quality control of biologics to customers in the pharmaceutical and medical technology industries. The Company markets several enzyme products (“SmartEnzymes”) in innovative product formats all over the world. The organization consists of Genovis AB and the wholly owned subsidiary Genovis Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North American market and Genovis AB handles sales in the rest of the world. Genovis shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s Certified Adviser, t: +46(0) 31 745 50 00. This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.
HALF-YEARLY REPORT JANUARY – JUNE 2016 January - June
Top 10 Most Recent News Articles
Copper Peptides Shine in New Renue Blue Cream
Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...
Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest
Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...
Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights
Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...
Continue Reading
Choate's Expands to New Mid-South Markets
Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...
Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts
Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...
Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron
A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...
Continue Reading
AI Alliance Rethinks Health Plan Engagement
Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...
Continue Reading
The Melt Grabs Top Spot in Burger Ratings War
Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...
Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday
A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...
Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context
Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...
Continue ReadingTop 5 Most Recently Viewed Articles
Epson Robots Unveils Cutting-Edge Automation Tech at Expo
Innovative Automation Solutions by Epson Robots Epson Robots is set to showcase its latest high-performance automation solutions at an upcoming major tradeshow. The focus will be on the exciting advancements in the SCARA and 6-Axis robots, which are recognized globally for their efficiency and precision in various industries. Exciting New Product Launches At the event,...
Continue Reading
Rexel Reports Fourth Quarter Growth Amid Market Challenges
Rexel's Financial Performance Overview Rexel has released its fourth quarter (Q4) and full year (FY) financial results, showcasing strong performance amid challenging market conditions. The company's FY 2024 sales reached €19,285.1 million, reflecting a modest year-on-year increase of 0.7% on a reported basis. This growth narrative underscores Rexel's effective...
Continue Reading
Monster Beverage Sees Gains in 2025 First Quarter Results
Monster Beverage's Impressive First Quarter Growth 2025 First Quarter Highlights The financial landscape for Monster Beverage Corporation (NASDAQ: MNST) revealed compelling growth in the first quarter of 2025. Gross profit as a percentage of net sales improved significantly, reaching 56.5 percent. The company reported an operating income increase of 5.1 percent, totaling...
Continue Reading
Transforming Metastatic HR+/HER2- Breast Cancer Care Innovations
Transforming Treatment Strategies for Metastatic HR+/HER2- Breast Cancer In recent years, the landscape of metastatic HR+/HER2- breast cancer treatment has evolved dramatically. With innovative therapies coming to the forefront, patients now have access to a wider range of treatment options that aim to improve survival rates and quality of life. The rise of targeted...
Continue Reading
Oil Price Surge Driven by Manufacturing Growth in China
Understanding the Recent Trends in Oil Prices Oil prices experienced an uptick recently, driven by promising signs from China's manufacturing sector. Reports reveal that China's factory activity demonstrated growth in December, marking it as a significant development in the global oil landscape. However, despite this positive news, oil prices are on a trajectory to finish...
Continue Reading